## **Aurum Pharmaceuticals Limited**

**Report and Financial Statements** 

30 June 2010

Company Number: 2581060

WEDNESDAY

A60

23/03/2011 COMPANIES HOUSE

142

## Aurum Pharmaceuticals Limited

Registered No 2581060

## **Directors**

T Engelen M Sıllıtto P Parry R deSouza

Registered Office Bampton Road Harold Hill Romford RM3 8UG

## **Directors' report**

The directors present their report and financial statements for the year ended 30 June 2010

#### Review of the business

The company did not trade during the year, did not incur any liabilities and consequently made neither a profit nor a loss

#### **Directors**

The directors who held office during the year are given below

A Oades

resigned 13 July 2010

T Engelen - Chairman

appointed 12 May 2010

P Parry

appointed 6 August 2010

R deSouza

appointed 28 September 2010

M Sıllıtto

## Parent ownership change

On the 12 May, 2010 Cardinal Health Inc sold the parent company, Cardinal Health UK 433 Ltd to Bolt Mezzanine Ltd

On behalf of the Board

M Sıllıtto Director

22 December 2010

# Statement of directors' responsibilities in respect of the financial statements

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom. Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors are required to

- select suitable accounting policies and then apply them consistently,
- make judgements and estimates that are reasonable and prudent,
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements,
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business

The directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

## **Balance sheet**

as at 30 June 2010

| 7   | Notes | 2010<br>£     | 2009<br>£     |
|---|-------|---------------|---------------|
| Debtors   | 4     | 103           | 103           |
|   |       |               |               |
| Capital and reserves Called up share capital Capital redemption reserve Profit and loss account | 5     | 100<br>2<br>1 | 100<br>2<br>1 |
| Shareholders' funds   |       | 103           | 103           |

## **Audit Exemption Statement**

For the year ending 30 June 2010 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

## Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476, and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts

The financial statements were approved for issue by the board of directors and signed on its behalf by

M Sillitto Director

22 December 2010

Company Number 2581060

## Notes to the financial statements

at 30 June 2010

## 1. Accounting policies

#### Basis of preparation

The financial statements have been prepared under the historical cost convention in accordance with applicable United Kingdom accounting standards

## 2. Trading

The company did not trade during the year, did not incur any liabilities and consequently made neither a profit nor a loss

#### 3. Directors and employees

The directors did not receive any emoluments in respect of their services to the company had no employees during the year

## 4. **Debtors:** amounts falling due after more than one year

|                                    | 2010 | 2009 |
|------------------------------------|------|------|
|                                    | £    | £    |
| Amounts owed by group undertakings | 103  | 103  |
|                                    |      |      |

## 5. Called up share capital

| A11 |  |  |
|-----|--|--|
|     |  |  |
|     |  |  |

| Aunorisea  |  |       |
|--|--|-------|
|  | 2010   | 2009  |
|  | £  | £     |
| 900 ordinary 'A' shares of £1 each                                     | 900  | 900   |
| 100 ordinary 'B' shares of £1 each                                     | 100  | 100   |
|  | 1,000  | 1,000 |
|  |  |       |
| Allotted, called up and fully paid                                     |  |       |
|  | 2010   | 2009  |
|  | £  | £     |
| 100 ordinary 'A' shares of £1 each                                     | 100  | 100   |
| 100 ordinary 'B' shares of £1 each  Allotted, called up and fully paid | 100<br>1,000<br>============================== | 1,00  |

The 'A' and 'B' shares rank parı passu ın all respects

## 6. Related Party Transactions

Advantage has been taken of the exemption under FRS 8 "Related Party Transactions" with entities that are part of the Martindale Pharma (Holdings 1) group on the grounds that all the voting rights are controlled by that company

## Notes to the financial statements

at 30 June 2010

## 7. Ultimate parent undertaking

The immediate parent undertaking is Martindale Pharma (Holdings 1) Ltd which is the smallest and largest group to consolidate the company's financial statements. Copies of Martindale Pharma (Holdings 1) Ltd financial statements can be obtained from the Company Secretary at Bampton Road, Harold Hill, Romford RM3 8UG

AA Capital NEBO Fund II LP, a partnership registered in the United Kingdom, is the company's ultimate parent and controlling party